Cargando…
Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection
Massive production of efficacious SARS-CoV-2 vaccines is essential for controlling the ongoing COVID-19 pandemic. We report here the preclinical development of yeast-produced receptor-binding domain (RBD)-based recombinant protein SARS-CoV-2 vaccines. We found that monomeric RBD of SARS-CoV-2 could...
Autores principales: | Zang, Jinkai, Zhu, Yuanfei, Zhou, Yu, Gu, Chenjian, Yi, Yufang, Wang, Shuxia, Xu, Shiqi, Hu, Gaowei, Du, Shujuan, Yin, Yannan, Wang, Yalei, Yang, Yong, Zhang, Xueyang, Wang, Haikun, Yin, Feifei, Zhang, Chao, Deng, Qiang, Xie, Youhua, Huang, Zhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372230/ https://www.ncbi.nlm.nih.gov/pubmed/34408130 http://dx.doi.org/10.1038/s41421-021-00315-9 |
Ejemplares similares
-
Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022) -
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines
por: Yang, Yong, et al.
Publicado: (2021) -
saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern
por: Komori, Mai, et al.
Publicado: (2023) -
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
por: Zhang, Chao, et al.
Publicado: (2021) -
Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)